Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

ADMA Biologics

Tracked across 10 events · 646 articles · First seen Apr 01, 2026 · Last active Sep 08, 2026

Sentiment
8
Attention
6
Events
10
Relationships
12
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 -80
Regulatory
Impact: ADMA Biologics is the primary subject of the class action lawsuits and investigations due to allegations of channel stuffing, undisclosed related-party transactions, and misleading revenue growth, which caused its stock price to decline significantly.
Apr 01, 2026 · 301 articles
4 75
Business
Impact: ADMA Biologics received an $8 million strategic investment and formed a joint venture with Guangzhou-Israel Biotechnology Fund to advance its oncology pipeline in China, accelerating development of BND-67 and BND-22.
Jun 01, 2026 · 7 articles
2 60
Business
Impact: ADMA Biologics has been recognized on the CDP Supplier Engagement Assessment A List for the second consecutive year, demonstrating its leadership in engaging suppliers on climate-related issues and strong sustainability performance. This enhances its reputation and attractiveness to ESG-focused investors.
Jun 02, 2026 · 6 articles
2 20
Business
Impact: ADMA Biologics is the subject of the event; it retained its MSCI AAA ESG rating and was included in the MSCI Selection Indexes for the fourth consecutive year, reinforcing its sustainability leadership.
Jul 08, 2026 · 6 articles
2 -80
Regulatory
Impact: ADMA Biologics is the defendant in the securities class action, accused of making false and misleading statements. The lawsuit and allegations have led to a significant drop in its stock price and could result in substantial financial penalties and reputational harm.
Jun 14, 2026 · 294 articles
2 -40
Regulatory
Berger Montague, a national plaintiffs' law firm, announced an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, a biopharmaceutical company. The investigation focuses on whether ADMA engaged in…
Impact: ADMA Biologics is the subject of the investigation; allegations of channel-stuffing could damage its reputation, lead to regulatory action, and negatively affect its stock price.
Aug 17, 2026 · 6 articles
3 70
Business
Impact: ADMA Biologics was selected by Teikoku Seiyaku to provide microbial contract development and manufacturing services for KTP-001, enhancing its position as a global CDMO.
May 26, 2026 · 6 articles
2 20
Business
Impact: Kang Liu's former employer; indirectly referenced, no direct impact from this event.
Aug 11, 2026 · 7 articles
2 0
Business
Impact: ADMA Biologics is the licensor of Whitehawk's existing ADC assets, but is not directly involved in this collaboration.
Jul 07, 2026 · 7 articles
2 40
Business
Impact: ADMA Biologics is mentioned as a portfolio company of Legend Holdings, showing the investor's focus but not directly affected.
Jul 20, 2026 · 6 articles
Culper Research target ↔ ADMA Biologics ADMA Biologics is the target of an activist short campaign by Culper Research, f
Culper Research activist ↔ ADMA Biologics Culper Research acts as an activist short seller against ADMA Biologics, publish
Cantor Fitzgerald ↔ ADMA Biologics
Cantor Fitzgerald ↔ ADMA Biologics
Kahn Swick & Foti ↔ ADMA Biologics
Kahn Swick & Foti ↔ ADMA Biologics
Rosen Law Firm ↔ ADMA Biologics
Rosen Law Firm ↔ ADMA Biologics
ERGEN INTELLIGENCE
Track ADMA Biologics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.